New pill shows promise for early Parkinson's motor symptoms
NCT ID NCT06596005
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tested an experimental capsule called TJ0113 in 149 people with early-stage Parkinson's disease. Participants took either 200 mg, 400 mg, or a placebo daily for 12 weeks. The main goal was to see if the drug improved motor symptoms, measured by a standard rating scale. The study is complete, and results are pending.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TJ0113 capsule
What this could lead to
If successful, this could point toward a new oral treatment option to help control motor symptoms in early Parkinson's disease.
What could go wrong
This is an early Phase 2 trial with only 149 participants, so results may not apply to all patients. The study is completed but not yet published, and the drug may not improve symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310009, China